WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell
coming out of last week's Consumer Electronics Show (CES).
According to Frank McGillin, SVP and General Manager of Consumer Health
at NeuroMetrix, "In the first several days that the QuellRelief.com
website was live, we have had excellent traffic and an information
request signup rate of over 20%. This exceeds our original expectations
and reflects the need for a better solution for the over 100 million
Americans living with chronic pain."
In the past week, Quell was featured in original stories in well over 30
media outlets including, C|NET, Forbes, PC Magazine, Bloomberg,
Drugstore News and MAC World. The new product was also selected as one
of four finalist in the Engadget Best of CES 2015 Digital Health and
Quell is FDA cleared for treatment of chronic pain without a
prescription. It uses NeuroMetrix's proprietary non-invasive
neurostimulation technology to provide relief from chronic pain, such as
due to diabetes, sciatica, fibromyalgia, and degenerative knee
conditions. The advanced wearable device is lightweight and can be worn
during the day while active, and at night while sleeping. Users of the
device will also have the option of using their smartphone to
automatically track and personalize their pain therapy.
Consumers and medical professionals can visit QuellRelief.com
to learn more and sign up to receive information. The company expects to
begin taking pre-orders for Quell in March and to ship during the second
quarter. Quell will initially be available exclusively through doctor's
office and online.
NeuroMetrix is an innovative health-care
company that develops wearable medical technology and point-of-care
tests that help patients and physicians better manage chronic pain,
nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Source: NeuroMetrix, Inc.
News Provided by Acquire Media